Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yi-Na Wang"'
Publikováno v:
Oncology Letters
Advances in the immunology have identified that interleukin (IL)-17 and IL-35 are cytokines with diverse functions, serving important roles in autoimmune diseases and chronic inflammation. Checkpoint inhibitor pneumonitis (CIP) is focal or diffuse lu
Publikováno v:
Journal of Clinical Oncology. 39:e21193-e21193
e21193 Background: In the past 3 years, immunotherapy has revolutionized the treatment paradigm of advanced non–small cell lung cancer (NSCLC). Checkpoint inhibitors showed promising results in the treatment of patients with advanced NSCLC with imp
Autor:
Jianjun Qiao, Yi-na Wang, Xiaoling Jiang, Dingxian Zhu, Yingguo Ding, Sha Zhou, Lina Xu, Hong Fang, Juan Bai, Yinhua Wu
Publikováno v:
International journal of molecular medicine. 43(3)
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been frequently used in targeted therapy for lung cancer. However, the widespread use of gefitinib in targeted therapy for patients with lung cancer is hampered by its comm
Autor:
Quanren Wang, Shengxiang Ren, Jianhua Shi, Ying Cheng, Jianhua Chen, Ji Feng Feng, Jianxing He, Yu Yao, Ying Yang, Caicun Zhou, Jun Zhao, Zhiyong Ma, Guanghui Gao, Kangsheng Gu, Meijuan Huang, Zhihua Liu, Gongyan Chen, Yi Na Wang, Xinmin Yu
Publikováno v:
Journal of Clinical Oncology. 37:9112-9112
9112 Background: Our preclinical study suggested combination of PD-1 monoclonal antibody SHR-1210 and VEGFR 2 inhibitor apatinib significantly improved antitumor effects. This was an open-label, multi-center, phase 1/2 study of intravenous SHR-1210 p
Autor:
Xiaoxia Chen, Yi Na Wang, Fengying Wu, Xiaoyan Kang, Shengxiang Ren, Weijing Cai, Anwen Xiong, Wei Li, Quanren Wang, Caicun Zhou, Chunxia Su, Guanghui Gao, Tao Jiang
Publikováno v:
Journal of Clinical Oncology. 36:e21017-e21017
e21017Background: SHR-1210 is a selective, humanized, high-affinity IgG4-kappa monoclonal antibody against PD-1. Our preclinical data demonstrated a synergistic anti-tumor effect in vivo with simul...
Publikováno v:
Japanese journal of clinical oncology. 43(2)
Icotinib hydrochloride, a novel inhibitor of epidermal growth factor receptor tyrosine kinase, has been approved by the State Food and Drug Administration for the treatment of advanced non-small-cell lung cancer. Up to date, cutaneous response to ico
Publikováno v:
Journal of Clinical Oncology. 32:e19087-e19087
e19087 Background: Smoking remains the leading risk factor of NSCLC. Activating mutations in EGFR gene have been reported more frequently in never smokers than smokers with NSCLC. Female pts with squamous cell carcinomas of the lung (SQCLC) differ fr